On May 16th, the Centers for Medicare and Medicaid Services announced a final regulation for Medicare’s Part D drug benefit for 2020. The regulation backed off of a proposal that would have created significant exceptions to requirements that Part D plans cover all drugs in six “protected classes”.
High and rising drug prices jeopardize consumers’ health and well-being.1 To address the harms of high drug prices, families across America want and deserve meaningful reforms that target and reduce the underlying “list” prices of drugs. Polling shows that nine out of 10 voters support allowing the government to negotiate lower drug prices in Medicare.2
Achieving Health Equity for Asian Americans, Native Hawaiians, and Pacific Islanders requires recognizing their diversity and disaggregating data.
Asian American, Native Hawaiian, and Pacific Islander Heritage month is an opportunity to focus on the many contributions these communities have made to build our nation over the generations, and their continued role in our future prosperity.
Trump Administration Proposal Redefines Poverty to Raise Health Care Costs for Middle-Class Families
For the second time in less than a month, the Trump administration has proposed obscure bureaucratic formula changes that will raise health care costs for 8.2 million people who buy private insurance using federal premium tax credits (PTCs). The latest move changes the definition of inflation that affects the federal poverty level (FPL), which is used to determine eligibility for many need-based programs.
In this testimony before the U.S. House of Representatives Energy and Commerce Committee on May 21, 2019, Frederick Isasi, Executive Director of Families USA, breaks down the problem with high drug prices and potential solutions under consideration by the committee. While high drug prices are a source of seemingly constant debate in Washington, D.C., for millions of America’s families, they are a painful and burdensome reality and can impact the basic necessities of life.
Drug companies consistently set high prices, which forces families to make impossible choices between their health care and other basic needs. Drug companies set exorbitant prices by design to maximize their profits, while making misleading claims that high prices simply fund innovative new drugs. Despite this gaming, our political system makes it easy for drug companies to continue exploitative pricing. This piece explains how our current drug pricing system leads to unaffordable prescription drugs, and ultimately harms people’s health.
On April 18, 2019, the Trump Administration finalized the Notice of Benefit and Payment Parameters for 2020 (NBPP). This rule will govern health insurance marketplaces and set the framework for insurance companies to propose plans and premium rates for 2020. Consumer advocates achieved several important victories in the final 2020 NBPP. Contrarily, the final rule also establishes harmful changes that will decrease access to high-quality, affordable coverage and care for families across the country.
Families USA, in partnership with American Academy of Family Physicians, American Benefits Council, American Federation of State, Country, and Municipal Employees, American Federation of Teachers, First Focus, and Pacific Business Group on Health, is launching Consumers First: The Alliance to Make the Health Care System Work for Everyone.
Families USA submitted the attached letter to U.S. House of Representatives Leadership in support of H.R. 987, the Strengthening Health Care and Lowering Prescription Drug Costs Act.